“Melanoma inhibitory activity” (MIA): a promising serological tumour marker in metastatic uveal melanoma

Reiniger, I. W.; Schaller, U. C.; Haritoglou, Christos; Hein, Rüdiger; Bosserhoff, Anja‐Katrin; Kampik, Anselm; Mueller, A. J.

doi:10.1007/s00417-005-1171-4

Cited by 29 publications

(34 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This confirms our previous results [6,7,8] and suggests that both markers are independent of tumor size. In all three groups the plasma levels of both markers were statistically similar to those in healthy control groups [15].…”

Section: Discussionsupporting

confidence: 81%

“…As in earlier studies [6,7,8] we were again able to demonstrate that elevated MIA plasma levels indicate metastatic disease also in the malignant melanoma of the uvea. These results have recently been confirmed by Barak et al [17].…”

Section: Discussionsupporting

confidence: 68%

“…As 1 patient in our study group developed metastases during the observation period, we were able to observe a marked increase for both MIA and OPN plasma levels along with the generalization of the tumor. This indicates that, in addition to the registration of single values of OPN or MIA plasma levels, the development or deviation from individual baseline values of these plasma levels over time should be taken into account [6, 7, 19]. …”

Section: Discussionmentioning

confidence: 99%

“…Two promising proteins have recently been reported, namely ‘melanoma inhibitory activity’ (MIA) [6,7,8] and osteopontin (OPN) [9, 10]. The latter is expressed by various cell types and its expression has been shown to enhance tumorigenicity and metastases [11], to lead to more aggressive tumor growth in various cancers [12] and to increase the invasive behavior of cutaneous melanoma cells [13].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Osteopontin and ‘Melanoma Inhibitory Activity’: Comparison of Two Serological Tumor Markers in Metastatic Uveal Melanoma Patients

Haritoglou¹,

Wolf²,

Maier

et al. 2009

Ophthalmologica

View full text Add to dashboard Cite

Background: Evaluation of the protein osteopontin (OPN) as a potential new marker in comparison to melanoma inhibitory activity (MIA) for screening and detection of metastatic uveal melanoma. Methods: Plasma levels of 32 patients with uveal melanoma were analyzed for OPN and MIA by enzyme-linked immunosorbent assay (ELISA). Fourteen of these patients had clinically detectable liver metastases. Results: Median plasma concentration of OPN in patients with metastatic disease was 152.01 ng/ml compared to 47.39 ng/ml in patients without clinically detectable metastases (p < 0.001). The difference between the median MIA plasma levels in patients with (13.11 ng/ml) and patients without (5.64 ng/ml) metastatic disease was also statistically significant (p < 0.001). No correlation could be found between MIA or OPN levels and tumor height in patients without clinically detectable metastases. Conclusion: The proteins MIA and OPN seem to be promising tumor markers for the metastasis screening in patients with uveal melanoma.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionsupporting

confidence: 68%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Osteopontin and ‘Melanoma Inhibitory Activity’: Comparison of Two Serological Tumor Markers in Metastatic Uveal Melanoma Patients

Haritoglou¹,

Wolf²,

Maier

et al. 2009

Ophthalmologica

View full text Add to dashboard Cite

show abstract

“…Other serum markers have been analyzed in the context of metastasis detection in UM patients by different groups [22][23][24][25]. A significant increase in the serum levels of the melanoma inhibitory activity protein (MIA) was detected in UM patients who developed metastases.…”

Section: Discussionmentioning

confidence: 99%

GDF-15: a novel serum marker for metastases in uveal melanoma patients

Suesskind

Schatz

Schnichels

et al. 2011

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

Clinical, Pathologic, and Imaging Features and Biological Markers of Uveal Melanoma

Rashid¹,

Grossniklaus²

2013

Methods in Molecular Biology

View full text Add to dashboard Cite

Uveal melanoma has unique clinical and pathologic features including virtually exclusive metastasis to the liver in high-risk cases. In this chapter, the clinical findings in uveal melanoma and diagnostic methods including imaging tests and serum markers are described. Additionally, the histopathologic features including the modified Callender classification and immunohistochemical findings of uveal melanoma are described.

show abstract

“Melanoma inhibitory activity” (MIA): a promising serological tumour marker in metastatic uveal melanoma

Abstract: The elevation of MIA serum levels in patients with metastatic disease from melanoma supports its promising role as a serum marker for monitoring patients with uveal melanoma.

Cited by 29 publications

References 27 publications

Osteopontin and ‘Melanoma Inhibitory Activity’: Comparison of Two Serological Tumor Markers in Metastatic Uveal Melanoma Patients

Osteopontin and ‘Melanoma Inhibitory Activity’: Comparison of Two Serological Tumor Markers in Metastatic Uveal Melanoma Patients

GDF-15: a novel serum marker for metastases in uveal melanoma patients

Clinical, Pathologic, and Imaging Features and Biological Markers of Uveal Melanoma

Contact Info

Product

Resources

About